eNOS (endothelial nitric oxide synthase)

eNOS — endothelial nitric oxide synthase, gene symbol NOS3 — is the enzyme that catalyses production of nitric oxide from L-arginine in vascular endothelial cells. eNOS activation downstream of Akt is the terminal step in the most-cited BPC-157 mechanistic cascade and a focal point for peptide-research framing of vascular function.

Definition

Endothelial nitric oxide synthase is one of three nitric oxide synthase isoforms expressed in mammalian tissues (alongside neuronal NOS and inducible NOS). Constitutively expressed on the vascular endothelium, eNOS catalyses the five-electron oxidation of L-arginine to L-citrulline with release of nitric oxide (NO) gas. Released NO diffuses to underlying vascular smooth muscle where it activates soluble guanylate cyclase, raises cyclic GMP, and produces vasodilation. NO also contributes to platelet inhibition, leukocyte adhesion suppression, and a wide set of secondary signalling responses across the endothelium and surrounding tissue.

Regulation occurs at three levels: gene expression (slow), post-translational modification (fast), and substrate/cofactor availability. The acute regulatory step for the BPC-157 literature is Akt-mediated phosphorylation on Ser1177, which raises catalytic activity within minutes of receptor engagement upstream.

How eNOS is studied in peptide research

eNOS activation is measured by Western blot for phospho-eNOS (Ser1177) alongside total eNOS, by direct NO quantitation in cell-culture supernatant or tissue (Griess assay, electrochemical NO probe, or DAF fluorescent indicators), and by pharmacological NO-synthase inhibition (L-NAME, L-NMMA) to confirm the contribution of eNOS to an observed functional outcome. When NOS inhibition reverses the peptide’s effect, the eNOS pathway is implicated as causal.

BPC-157 engagement of the VEGFR2-Akt-eNOS cascade in vascular endothelial cells was documented with NO release as a downstream readout (PMID 27847966). The Sikiric group’s nitric-oxide-system synthesis frames eNOS-driven NO output as central to the compound’s vascular and cytoprotective findings (PMID 23755725). Extension to ischemic-stress and collateral-circulation models (PMID 35125818) and the 2024 comprehensive review integrating gastric, vascular, and multi-organ findings (PMID 38980576) keep eNOS at the centre of the mechanistic map.

Related terms

• VEGFR2
• Akt signalling
• Angiogenesis
• Nitric oxide (NO)
• L-arginine / L-citrulline
• Soluble guanylate cyclase
• Vasodilation

Compounds where eNOS appears in the mechanism literature

• BPC-157 — eNOS activation downstream of VEGFR2-Akt is the terminal step in the most-cited mechanistic cascade for the compound
• TB-500 — vascular-perfusion and angiogenic findings intersect with NO-system signalling in endothelial-cell models
• GHK-Cu — copper-dependent vascular signalling has been examined in adjacent endothelial-function contexts

References

1. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
2. Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des 2014;20(7):1126-1135. [PMID 23755725]
3. Sikiric P et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances. World J Gastroenterol 2022;28(1):1-22. [PMID 35125818]
4. Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]

Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.